Sarcomatrix Therapeutics

About the offering

Sarcomatrix is in the pre-revenue and pre-commercialization stages of development. The Company is in pursuit of a license agreement for certain intellectual property ("IP") with the University of Nevada, Reno. We're committed to enhancing the lives of those with muscle diseases, and with two major assets nearing first-in-human clinical trials, [supported by $8M in NIH grants], including $2M to complete pre-clinical research, we’re seeking to transform treatment possibilities and shape a healthier future. Sarcomatrix is working to unveil novel therapeutics that we believe will disrupt the $2B Duchenne Muscular Dystrophy market, where current treatments merely delay progression. With a projected $18B global market by 2030 and Duchenne Muscular Dystrophy representing a quarter of all muscular dystrophies, we believe our approach holds disruptive medical potential. We've secured $8M in NIH grants in combination with our research partner, Strykagen. Your investment helps to fuel our mission-driven approach to reshape treatment paradigms in the biotech sector. THE PITCH Innovative Therapeutics for Longer and Stronger Lives At Sarcomatrix, our innovative approach aims to target the root causes of neuromuscular disorders, such as Muscular Dystrophy, Sarcopenia, and Cachexia, rather than merely addressing symptoms–offering a promising pathway towards a better quality of life. We believe this bold strategy positions us uniquely in the biotech landscape. With NIH grants, a visionary CEO, and an anticipated backing from Battle Born Venture, we aim to redefine standards of care and are gearing up for first-in-human clinical trials and an IND filing. Our mission is deeply rooted in scientific advancements, leveraging breakthroughs in muscle regeneration to offer hope to those affected by these debilitating conditions. THE PROBLEM & OUR SOLUTION Effective Treatments Powered by Science At Sarcomatrix, we're dedicated to addressing the pressing issue of muscle wasting diseases, starting with muscular dystrophies and expanding to include conditions like cachexia and sarcopenia. Our method is comprehensive: not only do we address muscle weakness, but we also provide crucial support to the diaphragm and heart, enhancing overall quality of life and extending longevity for the 14 million individuals facing neuromuscular disorders daily. *Images are computer-generated versions. Product is still currently under development With a focus on supporting vital muscle functions, our programs include a small molecule program and a protein replacement initiative. These dual pathways have the potential to allow us to tackle the complexities of muscle diseases from multiple angles, offering a holistic approach to treatment. Grounded in extensive research on the interaction between muscle cells and the Extracellular Matrix (ECM), our innovative approach focuses on targeting α7β1 integrin and laminin. Through our robust drug discovery platform and proprietary screening system, we're seeking to develop a portfolio of compounds with the potential to restore normal muscle function. THE MARKET & OUR TRACTION Fueling Hope and Empowering Progress Sarcomatrix is advancing two anticipated flagship drugs, S-969 and LAM111, with the backing of $8 million in NIH grants. The Duchenne Muscular Dystrophy market, currently valued at $2 billion1, presents immense growth potential, projected to soar to $18 billion worldwide by 20302. With exclusive worldwide product licensing, active Orphan Drug applications, and anticipated strategic funding initiatives like the Battle Born Venture Fund soft circled, we believe we’re positioned for substantial traction and market impact. (Source) We’re in the process of securing a license for a patent portfolio consisting of over 75 patents, which could help us protect drugs like S-969 and LAM111. With a solid foundation of IP in the works, a powerhouse team of geneticists, chemists, and innovators with 130+ years of experience and a track record of delivering over 20 medicines to the public, Sarcomatrix is on track to revolutionize treatment strategies for muscle disorders. WHY INVEST Muscle Matters Invest in Sarcomatrix, where our anticipated pioneering biotech has the potential to meet compassionate innovation. With a mission to improve lives affected by muscle diseases, we feel that Sarcomatrix is on the brink of groundbreaking clinical trials, offering investors a chance to become vital allies in the battle against muscular disorders, and part of our transformative journey. The potential to reshape the Duchenne Muscular Dystrophy community is truly profound. Join us as we embark on our first non-human primate study, a crucial step towards bringing life-changing treatments to those in need. Together, let's make a real-world difference.

FAQ